Elanco Animal Health Gets USDA Approval for Canine-Dermatitis Treatment
By Elias Schisgall
Elanco Animal Health received approval from the Agriculture Department for Befrena, the company's antibody treatment for canine allergic and atopic dermatitis.
The animal-medicine company said Wednesday that the injectable treatment is expected to launch in the first half of 2026.
It said Befrena was the company's second canine-dermatology product to be approved in the past 18 months, joining Zenrelia. The company estimates the size of the canine-dermatology market to be about $1.3 billion.
"The animal health sector is increasingly focused on antibody-based therapies, and today's approval is an important step forward in delivering high-impact innovation that enhances the quality of life for pets," Ellen de Brabander, Elanco's executive vice president of research and development, said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
December 31, 2025 14:33 ET (19:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States